135 related articles for article (PubMed ID: 29356025)
1. Identification and Therapeutic Intervention of Coactivated Anaplastic Lymphoma Kinase, Fibroblast Growth Factor Receptor 2, and Ephrin Type-A Receptor 5 Kinases in Hepatocellular Carcinoma.
Wang X; Zhang M; Ping F; Liu H; Sun J; Wang Y; Shen A; Ding J; Geng M
Hepatology; 2019 Feb; 69(2):573-586. PubMed ID: 29356025
[TBL] [Abstract][Full Text] [Related]
2. Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
Chen B; Wei W; Ma L; Yang B; Gill RM; Chua MS; Butte AJ; So S
Gastroenterology; 2017 Jun; 152(8):2022-2036. PubMed ID: 28284560
[TBL] [Abstract][Full Text] [Related]
3. Dual Targeting of Histone Methyltransferase G9a and DNA-Methyltransferase 1 for the Treatment of Experimental Hepatocellular Carcinoma.
Bárcena-Varela M; Caruso S; Llerena S; Álvarez-Sola G; Uriarte I; Latasa MU; Urtasun R; Rebouissou S; Alvarez L; Jimenez M; Santamaría E; Rodriguez-Ortigosa C; Mazza G; Rombouts K; San José-Eneriz E; Rabal O; Agirre X; Iraburu M; Santos-Laso A; Banales JM; Zucman-Rossi J; Prósper F; Oyarzabal J; Berasain C; Ávila MA; Fernández-Barrena MG
Hepatology; 2019 Feb; 69(2):587-603. PubMed ID: 30014490
[TBL] [Abstract][Full Text] [Related]
4. A selective c-Met and Trks inhibitor Indo5 suppresses hepatocellular carcinoma growth.
Luo T; Zhang SG; Zhu LF; Zhang FX; Li W; Zhao K; Wen XX; Yu M; Zhan YQ; Chen H; Ge CH; Gao HY; Wang L; Yang XM; Li CY
J Exp Clin Cancer Res; 2019 Mar; 38(1):130. PubMed ID: 30885237
[TBL] [Abstract][Full Text] [Related]
5. Targeting HSP90 with the small molecule inhibitor AUY922 (luminespib) as a treatment strategy against hepatocellular carcinoma.
Augello G; Emma MR; Cusimano A; Azzolina A; Mongiovì S; Puleio R; Cassata G; Gulino A; Belmonte B; Gramignoli R; Strom SC; McCubrey JA; Montalto G; Cervello M
Int J Cancer; 2019 May; 144(10):2613-2624. PubMed ID: 30488605
[TBL] [Abstract][Full Text] [Related]
6. Identification of a new TRAF6 inhibitor for the treatment of hepatocellular carcinoma.
Li N; Luo L; Wei J; Liu Y; Haque N; Huang H; Qi Y; Huang Z
Int J Biol Macromol; 2021 Jul; 182():910-920. PubMed ID: 33865893
[TBL] [Abstract][Full Text] [Related]
7. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ
Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344
[TBL] [Abstract][Full Text] [Related]
8. ψ-Bufarenogin, a novel anti-tumor compound, suppresses liver cancer growth by inhibiting receptor tyrosine kinase-mediated signaling.
Ding J; Wen W; Xiang D; Yin P; Liu Y; Liu C; He G; Cheng Z; Yin J; Sheng C; Zhang W; Nan F; Ye W; Zhang X; Wang H
Oncotarget; 2015 May; 6(13):11627-39. PubMed ID: 25890498
[TBL] [Abstract][Full Text] [Related]
9. Mannose-mediated inhibitory effects of PA-MSHA on invasion and metastasis of hepatocellular carcinoma via EGFR/Akt/IκBβ/NF-κB pathway.
Li T; Dong ZR; Guo ZY; Wang CH; Zhi XT; Zhou JW; Li DK; Chen ZT; Chen ZQ; Hu SY
Liver Int; 2015 Apr; 35(4):1416-29. PubMed ID: 25066210
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells.
Blivet-Van Eggelpoël MJ; Chettouh H; Fartoux L; Aoudjehane L; Barbu V; Rey C; Priam S; Housset C; Rosmorduc O; Desbois-Mouthon C
J Hepatol; 2012 Jul; 57(1):108-15. PubMed ID: 22414764
[TBL] [Abstract][Full Text] [Related]
11. Identification of mTOR as a primary resistance factor of the IAP antagonist AT406 in hepatocellular carcinoma cells.
Zhen MC; Wang FQ; Wu SF; Zhao YL; Liu PG; Yin ZY
Oncotarget; 2017 Feb; 8(6):9466-9475. PubMed ID: 28036295
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of eukaryotic initiation factor 4E phosphorylation by cercosporamide selectively suppresses angiogenesis, growth and survival of human hepatocellular carcinoma.
Liu Y; Sun L; Su X; Guo S
Biomed Pharmacother; 2016 Dec; 84():237-243. PubMed ID: 27662474
[TBL] [Abstract][Full Text] [Related]
13. Novel role of apatinib as a multi-target RTK inhibitor in the direct suppression of hepatocellular carcinoma cells.
Li X; Xu A; Li H; Zhang B; Cao B; Huang J
Biochim Biophys Acta Mol Basis Dis; 2018 May; 1864(5 Pt A):1693-1701. PubMed ID: 29486282
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib.
Tong M; Che N; Zhou L; Luk ST; Kau PW; Chai S; Ngan ES; Lo CM; Man K; Ding J; Lee TK; Ma S
J Hepatol; 2018 Oct; 69(4):826-839. PubMed ID: 29885413
[TBL] [Abstract][Full Text] [Related]
15. Dasatinib synergises with irinotecan to suppress hepatocellular carcinoma via inhibiting the protein synthesis of PLK1.
Xu L; Zhu Y; Shao J; Chen M; Yan H; Li G; Zhu Y; Xu Z; Yang B; Luo P; He Q
Br J Cancer; 2017 Apr; 116(8):1027-1036. PubMed ID: 28267710
[TBL] [Abstract][Full Text] [Related]
16. A phosphokinome-based screen uncovers new drug synergies for cancer driven by liver-specific gain of nononcogenic receptor tyrosine kinases.
Fan Y; Arechederra M; Richelme S; Daian F; Novello C; Calderaro J; Di Tommaso L; Morcrette G; Rebouissou S; Donadon M; Morenghi E; Zucman-Rossi J; Roncalli M; Dono R; Maina F
Hepatology; 2017 Nov; 66(5):1644-1661. PubMed ID: 28586114
[TBL] [Abstract][Full Text] [Related]
17. Cyclovirobuxine D Exerts Anticancer Effects by Suppressing the
Zhang J; Chen Y; Lin J; Jia R; An T; Dong T; Zhang Y; Yang X
DNA Cell Biol; 2020 Mar; 39(3):355-367. PubMed ID: 31913706
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-206 prevents the pathogenesis of hepatocellular carcinoma by modulating expression of met proto-oncogene and cyclin-dependent kinase 6 in mice.
Wu H; Tao J; Li X; Zhang T; Zhao L; Wang Y; Zhang L; Xiong J; Zeng Z; Zhan N; Steer CJ; Che L; Dong M; Wang X; Niu J; Li Z; Yan G; Chen X; Song G
Hepatology; 2017 Dec; 66(6):1952-1967. PubMed ID: 28714063
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib pretreatment enhances radiotherapy through targeting MEK/ERK/NF-κB pathway in human hepatocellular carcinoma-bearing mouse model.
Chen JC; Chuang HY; Hsu FT; Chen YC; Chien YC; Hwang JJ
Oncotarget; 2016 Dec; 7(51):85450-85463. PubMed ID: 27863427
[TBL] [Abstract][Full Text] [Related]
20. Validation of VX2 as a Hepatocellular Carcinoma Model: Comparison of the Molecular Reaction of VX2 and HepG2 Tumor Cells to Sorafenib In Vitro.
Nass N; Streit S; Wybranski C; Jürgens J; Brauner J; Schulz N; Powerski M; Ricke J; Kalinski T; Dudeck O; Seidensticker M
Anticancer Res; 2017 Jan; 37(1):87-93. PubMed ID: 28011478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
